TABLE 3.

Regression Results for Falsification Test: Probability of Monthly Out-of-Pocket Costs Greater Than $0 and Monthly Out-of-Pocket Costs for Janus Kinase Inhibitors

Two-part model
Covariates	Odds of cost >$0 (First-stage model)	Cost ratios (Second-stage model)
	OR (95% CI)	Cost estimate (95% CI)
Intercept	1.05 (1.02-1.09)a	$402.54 (390.25-425.18)a
Time period
Prereduction	Reference
Postreduction	0.66 (0.64-0.70)a	1.15 (1.12-1.20)a

Model part one predicts the probability of monthly out-of-pocket costs >$0 and model part 2 predicts monthly out-of-pocket cost for PCSK9 inhibitors contingent on positive cost.

^a Significant at 0.05.